Teduglutide recombinant

Teduglutide recombinant is a polypeptide drug used for the treatment of short bowel syndrome (SBS). It is a glucagon-like peptide-2 (GLP-2) analog that promotes the growth of the intestinal lining.

Mechanism of Action

Teduglutide recombinant works by binding to the GLP-2 receptor, which is found in the gastrointestinal tract. This binding stimulates the growth of the intestinal lining, increasing its surface area and thereby improving nutrient absorption. This is particularly beneficial for patients with short bowel syndrome, who have a reduced ability to absorb nutrients due to a shortened or damaged intestine.

Uses

Teduglutide recombinant is primarily used for the treatment of short bowel syndrome. It is typically prescribed to patients who are dependent on parenteral support, with the goal of reducing this dependency.

Side Effects

Common side effects of teduglutide recombinant include abdominal pain, nausea, headache, and cold symptoms. More serious side effects can include intestinal obstruction and colorectal polyps.

History

Teduglutide recombinant was first approved by the Food and Drug Administration (FDA) in 2012 under the brand name Gattex. It was developed by NPS Pharmaceuticals, which was later acquired by Shire Pharmaceuticals.

See Also

• Short bowel syndrome
• Glucagon-like peptide-2
• Food and Drug Administration

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

   This article is a gastroenterology stub. You can help WikiMD by expanding it!